If it is present, the patient is Rh-positive. There is about an 85 percent chance that an Rh-negative person will make antibodies if transfused with Rh-positive blood, whereas other blood group antigens are not such strong immune stimulators. The screening test for unexpected not A or B antibodies covers about 25 that patients are most likely to make and can detect red cell antibodies that were generated in response to previous transfusions or pregnancies.
If the screen is positive, further testing is performed to identify the specificity of the antibody and select blood from a donor that lacks the corresponding antigen. More commonly, the antibody screen is negative and we can safely transfuse ABO compatible red cells despite other blood group differences between the donor and recipient that may be present.
The situation is a little different for transfusions of platelets rather than red cells, which occur with patients undergoing chemotherapy. Because A and B antigens are weakly expressed on platelets, they are less important in this case. Although there are antigens that are specific to platelets, it is rare for people to make antibodies against them even after repeated transfusions.
But HLA antigens, which are critically important in transplantation, are strongly expressed on platelets but only very weakly expressed on red cells. It is common for patients to make antibodies to HLA antigens in response to transfusions or pregnancy. When platelets are transfused to a patient with corresponding HLA antibodies they are very rapidly cleared from circulation, which is essentially immediate rejection of the transfusion.
Usually there is not a clinically evident reaction, as in case of incompatible red cell transfusion, but the platelet transfusion is ineffective. Such a patient can become refractory to platelet transfusion meaning that the platelet count does not rise and the patient experiences no benefit and may be at risk for serious bleeding.
Refractoriness to platelet transfusion is a serious problem in cancer chemotherapy and bone marrow transplantation. Unfortunately, it is much more difficult to test for HLA and platelet antibodies than it is to test for red cell antibodies. Platelet compatibility testing is done for patients who do not have a successful response after several platelet transfusions.
Things get even more complicated when white cells such as lymphocytes are transfused. Normally, there are very small numbers of viable white cells in most units of blood transfused today. People with normal immune systems can reject transfused donor lymphocytes, which is a good thing. If transfused lymphocytes are not rejected there can be problems. Hemorrhagic cystitis is a toxicity related with cyclophosphamide; however, several viral etiologies, including adenovirus and BK virus, have been reported [ 50 ].
HSCT patients with hemorrhagic cystitis may require RBC replacement proportional to its loss and platelet transfusion if the patient is thrombocytopenic. Tranexamic acid should be avoided because of possible clothing within the ureters. Bladder irrigation and platelet transfusion are the mainstay of the treatment. This procedure is the infusion of lymphocytes from the original stem cell donor after the transplant to augment an antitumor immune response or to be sure that the donor HSCs remain engrafted.
T cells of donor are supposed to attack residual cancer cells. Some authors recommend granulocyte transfusion in patients meet that criterion regardless of the cause of neutropenia [ 56 ]:.
Evidence of bacterial or fungal infection i. Chemotherapy and HSCT are the most common indications for granulocyte transfusion even though their use is rare in daily practice.
Family members and community donors both can donate granulocytes; however, donor must fulfill some criterion. Granulocyte harvesting by apheresis is performed by removing granulocytes and returning erythrocytes and plasma to the donor. This study serves to define engraftment, graft failure, and relapse. Then, blood products consistent with donor ABO typing should be used.
Blood product transfusion is an inevitable and critical component for the patient management. HSCT patients have special requirements regarding blood products transfusion. Transfusion services, hospitals, physicians, and other health care staff who take care of transplant patients should be aware of that those patients have specific and specialized transfusion requirements.
Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3. Help us write another book on this subject and reach those readers.
Login to your personal dashboard for more detailed statistics on your publications. Edited by A. Koopman-van Gemert. Edited by Erman Salih Istifli. We are IntechOpen, the world's leading publisher of Open Access books.
Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. Downloaded: Unfortunately the patient died, but Dr Starzl went on to develop many of the drugs and techniques that make long-term survival possible for liver transplant patients. The first truly successful liver transplant was performed in Louis Washkansky received the heart of a young woman. He died of pneumonia 18 days after the operation — but it proved a transplant was possible.
Frederick West received a heart from labourer Patrick Ryan who had died of head injuries. Around heart transplants are now performed in the UK every year.
Cornea transplants now save the sight of some patients in the UK every year. Donated corneas can be stored for up to four weeks before transplant and the Bristol centre sends some 1, corneas around the country for transplant surgery.
The Cox family from Wolverhampton led the public campaign in memory of Peter Cox, who died from a brain tumour in aged 24 and became a donor. The second is Barbara Ryder, a nurse from Cornwall who donates her kidney to Andy Loudon, a carpenter from Bedfordshire who has been on dialysis for two years.
In the UK only around 5, people die every year in circumstances where organ donation is possible. In April , NHS Blood and Transplant announced that for the first time ever, more than 1, people in the UK during the course of the previous financial year donated their organs after they died, meaning that more people than ever had received a transplant to transform their life.
Both types of transplant give the same result — the patient receives stem cells that will develop into a new immune system. The main difference is how the cells are collected from the donor. Their blood is passed through a small tube into a machine that collects the stem cells, and then returns the rest of the blood to the body. Your doctor will assess which method is most appropriate for you.
This is called conditioning therapy. The day after this finishes, your new stem cells will be infused into your blood in a similar way to a regular blood transfusion. When your new stem cells enter your blood, they will move to your bone marrow and start producing new blood cells. Over time, this leads to the development of your new immune system that can recognise and remove any remaining abnormal cells in your body.
It will also protect you against things like bacteria and viruses that can cause infections.
0コメント